These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29862617)

  • 1. Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.
    Kaku K; Kuroda S; Ishida K; Umeda Y
    Diabetes Obes Metab; 2018 Oct; 20(10):2490-2493. PubMed ID: 29862617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
    Kaku K; Ishida K; Shimizu K; Achira M; Umeda Y
    J Diabetes Investig; 2020 Mar; 11(2):373-381. PubMed ID: 31389201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
    Inagaki N; Onouchi H; Maezawa H; Kuroda S; Kaku K
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):191-7. PubMed ID: 25609193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
    Inagaki N; Sano H; Seki Y; Kuroda S; Kaku K
    J Diabetes Investig; 2016 Sep; 7(5):718-26. PubMed ID: 27181699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.
    Inagaki N; Sano H; Seki Y; Kuroda S; Kaku K
    J Diabetes Investig; 2018 Mar; 9(2):354-359. PubMed ID: 28836351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
    Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
    Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Inagaki N; Harashima SI; Kaku K; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Iijima H
    Diabetes Obes Metab; 2018 Apr; 20(4):812-820. PubMed ID: 29110384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.
    Kaku K
    Expert Opin Drug Saf; 2017 Nov; 16(11):1313-1322. PubMed ID: 28829213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
    Kaku K; Mori M; Kanoo T; Katou M; Seino Y
    Expert Opin Pharmacother; 2014 Oct; 15(15):2121-30. PubMed ID: 25190226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Chen Y; Liu X; Li Q; Ma J; Lv X; Guo L; Wang C; Shi Y; Li Y; Johnsson E; Wang M; Zhao J; Ji L
    Diabetes Obes Metab; 2018 Apr; 20(4):1044-1049. PubMed ID: 29144061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
    Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
    Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
    Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
    Nishimura R; Osonoi T; Koike Y; Miyata K; Shimasaki Y
    Adv Ther; 2019 Nov; 36(11):3096-3109. PubMed ID: 31562608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.